<DOC>
	<DOCNO>NCT00894647</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety imiquimod cream versus placebo cream use cryosurgery treatment actinic keratoses ( AKs ) .</brief_summary>
	<brief_title>Safety Effectiveness Study Actinic Keratosis Treatment Following Cryosurgery</brief_title>
	<detailed_description>In multicenter , randomize , double-blind , placebo-controlled study , efficacy safety imiquimod 3.75 % cream follow cryosurgery treat clinically typical visible palpable AK lesion face compare placebo cream . Based 1:1 randomization , approximately 120 subject apply imiquimod 3.75 % cream daily ( 500 mg cream daily [ 18.75 mg imiquimod ] ) approximately 120 subject apply placebo cream daily two 2-week period ( Cycle 1 Cycle 2 ) separate 2 week treatment . Subjects visit clinic 9 times—1 screening/cryosurgery visit ( additional visit might need screen period ass heal cryosurgery ) , 4 treatment visit ( treatment initiation Weeks 0 4 treatment follow-up end Weeks 2 6 ) , 4 posttreatment visit ( 4 , 8 , 14 , 20 week last administration study treatment end Week 6 ) . The total study duration subject , include 2-week screening period , 28 week . Prior cryosurgery , subject ≥10 clinically typical visible palpable AK lesion area exceed 25 cm^2 face eligible participation study . At screen , minimum 5 visible lesion treat cryosurgery , 5 14 visible lesion treat cryosurgery . Subjects least 5 AK lesion skin heal sufficiently cryosurgery eligible randomization either imiquimod 3.75 % placebo cream . Subjects apply 2 packet study cream ( 500 mg total ) thin layer entire face , avoid periocular area , lip , naris ; ear exclude assessment treatment . Study cream apply prior normal sleeping hour remove approximately 8 hour later mild soap water . Rest period daily treatment could approve investigator need , treatment resumption investigator 's discretion .</detailed_description>
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>In good general health Negative urine pregnancy test ( woman childbearing potential ) agree use approve method birth control enrol study . Prior cryosurgery , ≥ 10 clinically typical ( visible palpable ) AKs area exceed 25 cm2 face . Must cryosurgery 5 14 AKs face give informed consent prior receive study medication . Lesions previously treat cryosurgery must heal sufficiently prior randomization study cream . Following cryosurgery , ≥ 5 clinically typical ( visible palpable ) AKs area exceed 25 cm2 face suitable treatment study cream . Women pregnant , lactating , plan become pregnant study Had medical event within 90 day visit ( e.g. , stroke , heart attack , etc. ) . Have skin condition treatment area may make bad treatment imiquimod ( e.g. , rosacea , psoriasis , atopic dermatitis , eczema ) . Have receive specific treatments/medications treatment area within designated time period prior study treatment initiation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>actinic keratosis</keyword>
	<keyword>skin disease</keyword>
</DOC>